The Company That Made Ozempic Lost Half Its Value. Why? [$NVO]

Описание: Novo Nordisk ($NVO) didn't just join the weight-loss boom — it created it. Ozempic and Wegovy became the most wanted drugs on the planet, and Novo briefly became the most valuable company in all of Europe. Demand is still exploding. And yet its stock fell about 50% and now trades at under 12x earnings — the valuation of a business in slow decline, not the inventor of a once-in-a-generation drug. THE ANOMALY audits how the company that made the miracle drug ended up in the bargain bin while the miracle is still selling out — and the answer is that inventing a category and OWNING it are two different things.

THE ANOMALY
Novo made Ozempic, the drug everyone wants. Its stock lost half its value and trades at ~12x earnings. Why?

THE AUDIT
1) The fast-follower built a better drug. Eli Lilly's rival medicine (Zepbound) went head-to-head with Novo's Wegovy — patients on Lilly's drug lost about 50 lbs over 72 weeks vs about 33 on Novo's. In medicine, the best molecule wins. And Novo's big hope to leapfrog back ahead, its next-gen CagriSema, FAILED its own trial — it couldn't even prove it was as good as Lilly's drug. In 2025, Lilly's sales passed Novo's. The crown changed hands.
2) And the price is collapsing from below. Late in 2025 a US deal cut Wegovy's price by roughly 60-80%. And semaglutide — the molecule inside Ozempic and Wegovy — begins losing patent protection in markets like Canada, Brazil and China in 2026 (the patent cliff, when cheap copies flood in). Novo is crushed from both sides: a better competitor above, collapsing prices and generics below.
3) And management said it out loud. Novo guided that its 2026 sales and profit growth would slow dramatically — toward the single digits after years of racing ahead — and its own CEO told investors, plainly, that things will get worse before they get better. When the people who see the prescription data first tell you to brace, the market listens.

THE OTHER SIDE
This is also what a fallen champion looks like right before it becomes a bargain. Novo still owns one of the best franchises in medicine, a deep next-gen pipeline (including pills instead of injections), and the whole weight-loss market is growing so fast that even a strong number two could thrive. At under 12x earnings, you're paying a decline price for a company that still makes a drug the world is desperate for. Watch whether Novo's pipeline finally delivers a drug that matches or beats Lilly's, and whether its share of new prescriptions stops falling. If the pipeline answers Lilly, 12x will look like a steal; if not, cheap stays cheap for a reason.

WHAT SETTLES IT
The market isn't saying the drug is bad — Ozempic still works and demand is enormous. It's saying the MOAT cracked: being first to a category is only a moat until someone builds something better, and Lilly did. The tell was never the demand headlines — it was the head-to-head trial data and the price. For any category creator: a first-mover advantage lasts exactly until a better product arrives, and then the pioneer's cheap valuation isn't automatically a bargain — sometimes it's the market coldly pricing a permanent #2.

VERDICT: TOO EARLY — a fallen champion, not a broken business. Cheap because the moat cracked, not because demand did; the trial data (not the price tag) decides if it gets back up.

HONESTY NOTES
The drug still works and demand is still huge — the crash is about the MOAT (first ≠ best) and price, NOT the demand.
Figures (stock ~-50%, P/E ~11.75, Zepbound ~50 lb vs Wegovy ~33 lb, US price cut ~60-80%) are as of 2026-07-15; re-check current data.

Historical analog: the pioneer overtaken by a better-engineered rival — the first search engines gave way to Google, the first smartphones to the iPhone. First invents; best inherits.

Sources: Novo Nordisk results and guidance; head-to-head trial reporting (tirzepatide vs semaglutide); CagriSema trial reporting; US pricing / MFN reporting; FMP market data (2026-07-15).

Educational framework for reading a market anomaly, NOT investment advice, and NOT a recommendation to buy, sell, or hold Novo Nordisk or Eli Lilly. Do your own research. Nothing here is medical advice.

#NovoNordisk #NVO #Ozempic #Wegovy #EliLilly #Zepbound #GLP1 #valueinvesting #stockmarket #investing